Transgene SA (TRGNF)
USD 0.7
(0.0%)
USD 0.7
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.62 Million EUR | 183.37% |
| 2022 | -1.95 Million EUR | 5.47% |
| 2021 | -2.06 Million EUR | -34550.0% |
| 2020 | 6000.00 EUR | -99.96% |
| 2019 | 15.32 Million EUR | -58.58% |
| 2018 | 36.98 Million EUR | -8.74% |
| 2017 | 40.53 Million EUR | 0.36% |
| 2016 | 40.38 Million EUR | 21.92% |
| 2015 | 33.12 Million EUR | 1.31% |
| 2014 | 32.69 Million EUR | 8.34% |
| 2013 | 30.17 Million EUR | 39.1% |
| 2012 | 21.69 Million EUR | 13.23% |
| 2011 | 19.16 Million EUR | 1489.41% |
| 2010 | -1.37 Million EUR | 97.87% |
| 2009 | -64.69 Million EUR | -189.95% |
| 2008 | -22.31 Million EUR | -371766.67% |
| 2007 | -6000.00 EUR | 99.97% |
| 2006 | -20.32 Million EUR | 0.0% |
| 2004 | -9.59 Million EUR | 67.37% |
| 2003 | -29.4 Million EUR | 39.5% |
| 2002 | -48.6 Million EUR | 25.87% |
| 2001 | -65.56 Million EUR | -194.46% |
| 2000 | -22.26 Million EUR | 49.97% |
| 1999 | -44.5 Million EUR | 28.02% |
| 1998 | -61.82 Million EUR | -522.68% |
| 1997 | -9.92 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 21.37 Million EUR | 1212.03% |
| 2024 Q2 | 21.37 Million EUR | 0.42% |
| 2023 Q4 | 1.62 Million EUR | 318.77% |
| 2023 Q3 | 389 Thousand EUR | 120.69% |
| 2023 Q1 | 7.85 Million EUR | 501.74% |
| 2023 Q2 | -1.88 Million EUR | -123.95% |
| 2023 FY | 1.62 Million EUR | 183.37% |
| 2022 Q2 | -3.93 Million EUR | -148.68% |
| 2022 Q1 | 8.08 Million EUR | 491.15% |
| 2022 FY | -1.95 Million EUR | 5.47% |
| 2022 Q4 | -1.95 Million EUR | -124.66% |
| 2022 Q3 | 7.92 Million EUR | 301.32% |
| 2021 Q1 | 5.31 Million EUR | 88533.33% |
| 2021 Q2 | -6.95 Million EUR | -230.74% |
| 2021 Q4 | -2.06 Million EUR | -121.89% |
| 2021 FY | -2.06 Million EUR | -34550.0% |
| 2021 Q3 | 9.44 Million EUR | 235.83% |
| 2020 Q1 | 20.37 Million EUR | 32.99% |
| 2020 FY | 6000.00 EUR | -99.96% |
| 2020 Q2 | 8.92 Million EUR | -56.19% |
| 2020 Q3 | 11.82 Million EUR | 32.47% |
| 2020 Q4 | 6000.00 EUR | -99.95% |
| 2019 Q3 | 26 Million EUR | 51.67% |
| 2019 FY | 15.32 Million EUR | -58.58% |
| 2019 Q4 | 15.32 Million EUR | -41.08% |
| 2019 Q1 | 37.22 Million EUR | 0.63% |
| 2019 Q2 | 17.14 Million EUR | -53.94% |
| 2018 Q2 | 34.92 Million EUR | -35.56% |
| 2018 Q4 | 36.98 Million EUR | -34.43% |
| 2018 FY | 36.98 Million EUR | -8.74% |
| 2018 Q3 | 56.41 Million EUR | 61.52% |
| 2018 Q1 | 54.2 Million EUR | 33.72% |
| 2017 Q1 | 56.13 Million EUR | 39.0% |
| 2017 Q2 | 39.23 Million EUR | -30.1% |
| 2017 Q4 | 40.53 Million EUR | -31.6% |
| 2017 FY | 40.53 Million EUR | 0.36% |
| 2017 Q3 | 59.25 Million EUR | 51.02% |
| 2016 FY | 40.38 Million EUR | 21.92% |
| 2016 Q3 | 57.01 Million EUR | 43.21% |
| 2016 Q2 | 39.81 Million EUR | -29.43% |
| 2016 Q1 | 56.41 Million EUR | 70.31% |
| 2016 Q4 | 40.38 Million EUR | -29.16% |
| 2015 Q3 | 49.35 Million EUR | 21.3% |
| 2015 FY | 33.12 Million EUR | 1.31% |
| 2015 Q1 | 55.74 Million EUR | 70.5% |
| 2015 Q2 | 40.69 Million EUR | -27.0% |
| 2015 Q4 | 33.12 Million EUR | -32.89% |
| 2014 Q4 | 32.69 Million EUR | -31.28% |
| 2014 FY | 32.69 Million EUR | 8.34% |
| 2014 Q2 | 35.56 Million EUR | -28.87% |
| 2014 Q1 | 50 Million EUR | 65.69% |
| 2014 Q3 | 47.58 Million EUR | 33.79% |
| 2013 FY | 30.17 Million EUR | 39.1% |
| 2013 Q2 | 27.53 Million EUR | -27.02% |
| 2013 Q4 | 30.17 Million EUR | -30.66% |
| 2013 Q3 | 43.52 Million EUR | 58.07% |
| 2013 Q1 | 37.72 Million EUR | 73.9% |
| 2012 Q2 | -10.69 Million EUR | 0.0% |
| 2012 Q4 | 21.69 Million EUR | 0.0% |
| 2012 FY | 21.69 Million EUR | 13.23% |
| 2011 FY | 19.16 Million EUR | 1489.41% |
| 2011 Q4 | 19.16 Million EUR | 0.0% |
| 2011 Q2 | -13.79 Million EUR | 0.0% |
| 2010 Q2 | -1.21 Million EUR | 0.0% |
| 2010 FY | -1.37 Million EUR | 97.87% |
| 2010 Q4 | -1.37 Million EUR | 0.0% |
| 2009 Q4 | -64.69 Million EUR | 0.0% |
| 2009 FY | -64.69 Million EUR | -189.95% |
| 2009 Q2 | -81.63 Million EUR | 0.0% |
| 2008 FY | -22.31 Million EUR | -371766.67% |
| 2008 Q4 | -22.31 Million EUR | 0.0% |
| 2007 FY | -6000.00 EUR | 99.97% |
| 2006 FY | -20.32 Million EUR | 0.0% |
| 2005 Q2 | -4.47 Million EUR | 0.0% |
| 2004 Q4 | -9.59 Million EUR | 0.0% |
| 2004 Q2 | -24.81 Million EUR | 16.23% |
| 2004 Q1 | -29.62 Million EUR | -0.76% |
| 2004 FY | -9.59 Million EUR | 67.37% |
| 2003 FY | -29.4 Million EUR | 39.5% |
| 2003 Q3 | -40.73 Million EUR | 9.16% |
| 2003 Q4 | -29.4 Million EUR | 27.82% |
| 2003 Q1 | -49.86 Million EUR | -2.6% |
| 2003 Q2 | -44.84 Million EUR | 10.06% |
| 2002 FY | -48.6 Million EUR | 25.87% |
| 2002 Q4 | -48.6 Million EUR | 14.3% |
| 2002 Q1 | -66.52 Million EUR | -1.48% |
| 2002 Q3 | -56.7 Million EUR | 8.03% |
| 2002 Q2 | -61.66 Million EUR | 7.31% |
| 2001 Q3 | -78.17 Million EUR | 6.87% |
| 2001 Q2 | -83.94 Million EUR | -239.8% |
| 2001 FY | -65.56 Million EUR | -194.46% |
| 2001 Q4 | -65.56 Million EUR | 16.14% |
| 2001 Q1 | -24.7 Million EUR | -10.96% |
| 2000 Q4 | -22.26 Million EUR | 36.01% |
| 2000 Q1 | -43.75 Million EUR | 1.69% |
| 2000 Q2 | -41.1 Million EUR | 6.05% |
| 2000 Q3 | -34.79 Million EUR | 15.34% |
| 2000 FY | -22.26 Million EUR | 49.97% |
| 1999 FY | -44.5 Million EUR | 28.02% |
| 1999 Q4 | -44.5 Million EUR | 0.0% |
| 1998 Q4 | -61.82 Million EUR | 0.0% |
| 1998 FY | -61.82 Million EUR | -522.68% |
| 1997 FY | -9.92 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ContraFect Corporation | -6.02 Million USD | 127.033% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 89.666% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 60.442% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -305.376% |
| SQZ Biotechnologies Company | -36.23 Million USD | 104.495% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 27.349% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 96.193% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 125.839% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -75.693% |
| Marizyme, Inc. | 18.56 Million USD | 91.227% |
| Genus plc | 190.6 Million USD | 99.145% |
| Pharming Group N.V. | 109.8 Million USD | 98.516% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -89.366% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -34.197% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -139.559% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -40.987% |
| IMV Inc. | 7.67 Million USD | 78.763% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 70.392% |
| ONE Bio Corp. | 9.04 Million USD | 81.98% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 87.417% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -161.744% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -61.653% |
| Biomind Labs Inc. | 711.4 Thousand USD | -128.984% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 97.309% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 87.28% |
| Skye Bioscience, Inc. | -5.72 Million USD | 128.472% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -352.865% |
| Mesoblast Limited | 55.85 Million USD | 97.084% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -1065.203% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 71.16% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -8099.527% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 26.021% |
| GB Sciences, Inc. | 1.74 Million USD | 6.771% |
| MultiCell Technologies, Inc. | 90.04 USD | -1809095.913% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 986.347% |
| HST Global, Inc. | 96.79 Thousand USD | -1582.973% |
| CSL Limited | 10.52 Billion USD | 99.985% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Agentix Corp. | 37.63 Thousand USD | -4228.878% |
| Halberd Corporation | 144.72 Thousand USD | -1025.614% |
| Enzolytics Inc. | 981.65 Thousand USD | -65.944% |
| Resverlogix Corp. | 6.45 Million USD | 74.748% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 342.019% |
| argenx SE | -2.02 Billion USD | 100.08% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 103.465% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 94.668% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 118.428% |
| Bioxytran, Inc. | 1.89 Million USD | 14.214% |
| Zenith Capital Corp. | 10.06 Thousand USD | -16086.407% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 31.728% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -890.219% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 8992.892% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.153% |
| Kadimastem Ltd | -253.1 Thousand USD | 743.614% |
| Helix BioMedix, Inc. | -2.57 Million USD | 163.384% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 18.525% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 91.966% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 27.141% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -1109.902% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 321.941% |
| EV Biologics, Inc. | 1.36 Million USD | -19.081% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -709.425% |
| Q BioMed Inc. | 4.06 Million USD | 59.877% |
| LadRx Corporation | -2.03 Million USD | 179.991% |
| Cell Source, Inc. | 9.23 Million USD | 82.355% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 8082.164% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -156.468% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 96.249% |
| Itoco Inc. | 228.3 Thousand USD | -613.519% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -1097.891% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -689.945% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 76.962% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 67.137% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 39.859% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | -5.9 Million USD | 127.595% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -712.744% |
| NovAccess Global Inc. | 2.17 Million USD | 25.223% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 251877.434% |
| BioStem Technologies, Inc. | 4.47 Million USD | 63.573% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 17675.963% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 124451.145% |
| Qrons Inc. | 351.42 Thousand USD | -363.539% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 78.861% |
| SYBLEU INC | 473.71 Thousand USD | -243.878% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 752.592% |
| Rebus Holdings, Inc. | 305 Thousand USD | -434.098% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -156.468% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 63.451% |
| Affymax, Inc. | -5.59 Million USD | 129.105% |
| Mobile Lads Corp. | 484.23 Thousand USD | -236.409% |
| International Stem Cell Corporation | 2.59 Million USD | 37.104% |
| CytoDyn Inc. | 20.26 Million USD | 91.96% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -2510.033% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 25.306% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 52.563% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 80.954% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -110.845% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 230.32% |
| Neutra Corp. | 52.18 Thousand USD | -3021.467% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 165.448% |
| PureTech Health plc | -167.19 Million USD | 100.974% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 765.148% |
| IXICO plc | -4.44 Million USD | 136.651% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 87.677% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 97.03% |
| CSL Limited | 10.52 Billion USD | 99.985% |
| Cellectis S.A. | -43.81 Million USD | 103.718% |